• Genprex regained Nasdaq compliance with the $1 minimum bid price rule, following a Nasdaq Hearings Panel determination on Aug. 4, 2026.
• The panel will keep jurisdiction until Dec. 7, 2026, requiring the stock to close at or above $1 each trading day.
• Any new Nasdaq listing rule deficiency before Dec. 7 triggers a seven-day deadline to submit a cure plan, risking delisting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-025938), on August 05, 2026, and is solely responsible for the information contained therein.